The following medical procedures should be made available to each employee who is exposed to molybdenum and insoluble molybdenum compounds at potentially hazardous levels: Initial medical screening: Employees should be screened for history of certain medical conditions /kidney disease; chronic respiratory disease; liver disease/ which might place the employee at increased risk from molybdenum and insoluble molybdenum compounds exposure. Periodic medical exam: Any employee developing the above listed conditions should be referred for further medical examination. /Molybdenum and insoluble molybdenum compounds/
EXPOSURE TO MOLYBDENUM DISULFIDE LUBRICANT SPRAY ... MAY ... PROVE HAZARDOUS TO HEALTH. INSOL MOLYBDENUM CMPD SUCH AS MOLYBDENUM DISULFIDE ... ARE CHARACTERIZED BY LOW TOXICITY ... DERMATITIS FROM CONTACT WITH MOLYBDENUM DISULFIDE IS UNKNOWN.
... MOLYBDENUM CMPD EXHIBIT A LOW ORDER OF TOXICITY, BUT ... SOME DIFFERENCES IN TOXICITY MAY BE ASCRIBED TO DIFFERENT COMPOUNDS; THE TRIOXIDE AND AMMONIUM MOLYBDATE WERE MORE TOXIC THAN THE ORE MOLYBDENITE, THE METAL OR THE DIOXIDE. /MOLYBDENUM CMPD/
Determination of molybdenum in tissues (lung, liver, kidney, spleen, bone) of guinea pigs following 25 days of inhalation of subLD50 doses of the sulfide, the dust and fume of the trioxide, and calcium molybdate showed rather uniform distribution in the tissues, incl bone, for all substances at the end of the exposure. Values from 10 to 60 ug/10 g fresh tissue were common for all substances except molybdate trioxide and calcium molybdate dusts, which were higher by a two to four fold factor in the kidney, lung, spleen, and bone. Other exceptions were high lung retentions (40 and 18 times, respectively) for the sulfide and molybdate over that by other tissues according to the thiocyanate method of analysis.
